{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:54:51Z","timestamp":1780386891720,"version":"3.54.1"},"publisher-location":"Cham","reference-count":134,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319403182","type":"print"},{"value":"9783319403205","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-3-319-40320-5_14","type":"book-chapter","created":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T16:01:09Z","timestamp":1475337669000},"page":"251-270","source":"Crossref","is-referenced-by-count":24,"title":["Bone Disease in Multiple Myeloma"],"prefix":"10.1007","author":[{"given":"Homare","family":"Eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"David Roodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,2]]},"reference":[{"key":"14_CR1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565\u20131571","journal-title":"N Engl J Med"},{"key":"14_CR2","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","volume":"357","author":"M Dimopoulos","year":"2007","unstructured":"Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123\u20132132","journal-title":"N Engl J Med"},{"key":"14_CR3","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609\u20132617","journal-title":"N Engl J Med"},{"key":"14_CR4","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood-2007-08-104984","volume":"111","author":"H Brenner","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111:2521\u20132526","journal-title":"Blood"},{"key":"14_CR5","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1158\/1078-0432.CCR-10-1804","volume":"17","author":"N Raje","year":"2011","unstructured":"Raje N, Roodman GD (2011) Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 17:1278\u20131286","journal-title":"Clin Cancer Res"},{"key":"14_CR6","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588\u20131594","journal-title":"Cancer"},{"key":"14_CR7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","volume":"109","author":"GD Roodman","year":"2010","unstructured":"Roodman GD (2010) Pathogenesis of myeloma bone disease. J Cell Biochem 109:283\u2013291","journal-title":"J Cell Biochem"},{"key":"14_CR8","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","volume":"110","author":"F Saad","year":"2007","unstructured":"Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860\u20131867","journal-title":"Cancer"},{"key":"14_CR9","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","volume":"107","author":"S Vallet","year":"2010","unstructured":"Vallet S, Mukherjee S, Vaghela N et al (2010) Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 107:5124\u20135129","journal-title":"Proc Natl Acad Sci USA"},{"key":"14_CR10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s12307-011-0090-7","volume":"4","author":"S Vallet","year":"2011","unstructured":"Vallet S, Raje N (2011) Bone anabolic agents for the treatment of multiple myeloma. Cancer Microenviron 4:339\u2013349","journal-title":"Cancer Microenviron"},{"key":"14_CR11","doi-asserted-by":"crossref","unstructured":"Sonmez M, Akagun T, Topbas M, et al (2008) Effect of pathologic fractures on survival in multiple myeloma patients: a case control study. J Exp Clin Cancer Res 27:11-9966-27-11","DOI":"10.1186\/1756-9966-27-11"},{"key":"14_CR12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","volume":"23","author":"K Podar","year":"2009","unstructured":"Podar K, Chauhan D, Anderson KC (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23:10\u201324","journal-title":"Leukemia"},{"key":"14_CR13","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2007-03-077685","volume":"111","author":"CM Edwards","year":"2008","unstructured":"Edwards CM, Edwards JR, Lwin ST et al (2008) Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111:2833\u20132842","journal-title":"Blood"},{"key":"14_CR14","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/leu.2013.50","volume":"27","author":"T Scullen","year":"2013","unstructured":"Scullen T, Santo L, Vallet S et al (2013) Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy. Leukemia 27:1715\u20131721","journal-title":"Leukemia"},{"key":"14_CR15","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","volume":"108","author":"SJ Choi","year":"2001","unstructured":"Choi SJ, Oba Y, Gazitt Y et al (2001) Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 108:1833\u20131841","journal-title":"J Clin Invest"},{"key":"14_CR16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","volume":"26","author":"LF Bonewald","year":"2011","unstructured":"Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26:229\u2013238","journal-title":"J Bone Miner Res"},{"key":"14_CR17","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1359\/jbmr.060107","volume":"21","author":"JI Aguirre","year":"2006","unstructured":"Aguirre JI, Plotkin LI, Stewart SA et al (2006) Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res 21:605\u2013615","journal-title":"J Bone Miner Res"},{"key":"14_CR18","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/jbmr.168","volume":"25","author":"Y Kitase","year":"2010","unstructured":"Kitase Y, Barragan L, Qing H et al (2010) Mechanical induction of PGE2 in osteocytes blocks glucocorticoid-induced apoptosis through both the beta-catenin and PKA pathways. J Bone Miner Res 25:2657\u20132668","journal-title":"J Bone Miner Res"},{"key":"14_CR19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1359\/jbmr.080207","volume":"23","author":"G Kogianni","year":"2008","unstructured":"Kogianni G, Mann V, Noble BS (2008) Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction. J Bone Miner Res 23:915\u2013927","journal-title":"J Bone Miner Res"},{"key":"14_CR20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","volume":"19","author":"R Baron","year":"2013","unstructured":"Baron R, Kneissel M (2013) WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19:179\u2013192","journal-title":"Nat Med"},{"key":"14_CR21","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.2489","volume":"17","author":"T Negishi-Koga","year":"2011","unstructured":"Negishi-Koga T, Shinohara M, Komatsu N et al (2011) Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med 17:1473\u20131480","journal-title":"Nat Med"},{"key":"14_CR22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2141.1982.tb03936.x","volume":"52","author":"A Valentin-Opran","year":"1982","unstructured":"Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Arlot ME (1982) Quantitative histology of myeloma-induced bone changes. Br J Haematol 52:601\u2013610","journal-title":"Br J Haematol"},{"key":"14_CR23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","volume":"49","author":"T Taube","year":"1992","unstructured":"Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49:192\u2013198","journal-title":"Eur J Haematol"},{"key":"14_CR24","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"E Terpos","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF et al (2003) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102:1064\u20131069","journal-title":"Blood"},{"key":"14_CR25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","volume":"126","author":"M Politou","year":"2004","unstructured":"Politou M, Terpos E, Anagnostopoulos A et al (2004) Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 126:686\u2013689","journal-title":"Br J Haematol"},{"key":"14_CR26","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","volume":"103","author":"JW Lee","year":"2004","unstructured":"Lee JW, Chung HY, Ehrlich LA et al (2004) IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103:2308\u20132315","journal-title":"Blood"},{"key":"14_CR27","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1038\/leu.2009.136","volume":"23","author":"S Colucci","year":"2009","unstructured":"Colucci S, Brunetti G, Mori G et al (2009) Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients. Leukemia 23:2139\u20132146","journal-title":"Leukemia"},{"key":"14_CR28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1749-6632.2009.05304.x","volume":"1192","author":"G Brunetti","year":"2010","unstructured":"Brunetti G, Oranger A, Mori G et al (2010) The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3. Ann N Y Acad Sci 1192:298\u2013302","journal-title":"Ann N Y Acad Sci"},{"key":"14_CR29","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","volume":"100","author":"M Abe","year":"2002","unstructured":"Abe M, Hiura K, Wilde J et al (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100:2195\u20132202","journal-title":"Blood"},{"key":"14_CR30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2141.2003.04040.x","volume":"120","author":"S Uneda","year":"2003","unstructured":"Uneda S, Hata H, Matsuno F et al (2003) Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 120:53\u201355","journal-title":"Br J Haematol"},{"key":"14_CR31","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2011.43","volume":"25","author":"S Vallet","year":"2011","unstructured":"Vallet S, Pozzi S, Patel K et al (2011) A novel role for CCL3 (MIP-1alpha) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. Leukemia 25:1174\u20131181","journal-title":"Leukemia"},{"key":"14_CR32","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","volume":"15","author":"D Gupta","year":"2001","unstructured":"Gupta D, Treon SP, Shima Y et al (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15:1950\u20131961","journal-title":"Leukemia"},{"key":"14_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(03)00841-2","volume":"321","author":"MS Nanes","year":"2003","unstructured":"Nanes MS (2003) Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 321:1\u201315","journal-title":"Gene"},{"key":"14_CR34","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.4049\/jimmunol.173.8.4838","volume":"173","author":"H Kitaura","year":"2004","unstructured":"Kitaura H, Sands MS, Aya K et al (2004) Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo. J Immunol 173:4838\u20134846","journal-title":"J Immunol"},{"key":"14_CR35","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","volume":"98","author":"N Giuliani","year":"2001","unstructured":"Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S (2001) Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527\u20133533","journal-title":"Blood"},{"key":"14_CR36","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","volume":"98","author":"RN Pearse","year":"2001","unstructured":"Pearse RN, Sordillo EM, Yaccoby S et al (2001) Multiple myeloma disrupts the TRANCE\/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98:11581\u201311586","journal-title":"Proc Natl Acad Sci USA"},{"key":"14_CR37","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2141.2002.03417.x","volume":"117","author":"S Roux","year":"2002","unstructured":"Roux S, Meignin V, Quillard J et al (2002) RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 117:86\u201392","journal-title":"Br J Haematol"},{"key":"14_CR38","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood-2004-02-0474","volume":"104","author":"S Colucci","year":"2004","unstructured":"Colucci S, Brunetti G, Rizzi R et al (2004) T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG\/TRAIL interaction. Blood 104:3722\u20133730","journal-title":"Blood"},{"key":"14_CR39","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood.V96.5.1953","volume":"96","author":"T Michigami","year":"2000","unstructured":"Michigami T, Shimizu N, Williams PJ et al (2000) Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 96:1953\u20131960","journal-title":"Blood"},{"key":"14_CR40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/cbt.1.5.174","volume":"1","author":"T Hideshima","year":"2002","unstructured":"Hideshima T, Chauhan D, Hayashi T et al (2002) The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther 1:539\u2013544","journal-title":"Mol Cancer Ther"},{"key":"14_CR41","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1158\/0008-5472.CAN-06-0190","volume":"66","author":"YT Tai","year":"2006","unstructured":"Tai YT, Li XF, Breitkreutz I et al (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66:6675\u20136682","journal-title":"Cancer Res"},{"key":"14_CR42","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","volume":"87","author":"D Chauhan","year":"1996","unstructured":"Chauhan D, Uchiyama H, Akbarali Y et al (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87:1104\u20131112","journal-title":"Blood"},{"key":"14_CR43","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","volume":"82","author":"H Uchiyama","year":"1993","unstructured":"Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC (1993) Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82:3712\u20133720","journal-title":"Blood"},{"key":"14_CR44","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","volume":"101","author":"O Sezer","year":"2003","unstructured":"Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC (2003) RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101:2094\u20132098","journal-title":"Blood"},{"key":"14_CR45","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2011.381","volume":"26","author":"N Giuliani","year":"2012","unstructured":"Giuliani N, Ferretti M, Bolzoni M et al (2012) Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia 26:1391\u20131401","journal-title":"Leukemia"},{"key":"14_CR46","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/leu.2013.385","volume":"28","author":"R Silbermann","year":"2014","unstructured":"Silbermann R, Bolzoni M, Storti P et al (2014) Bone marrow monocyte-\/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma. Leukemia 28:951\u2013954","journal-title":"Leukemia"},{"key":"14_CR47","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2006-04-017087","volume":"108","author":"E Masih-Khan","year":"2006","unstructured":"Masih-Khan E, Trudel S, Heise C et al (2006) MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood 108:3465\u20133471","journal-title":"Blood"},{"key":"14_CR48","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2004-01-0041","volume":"104","author":"A Rivollier","year":"2004","unstructured":"Rivollier A, Mazzorana M, Tebib J et al (2004) Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 104:4029\u20134037","journal-title":"Blood"},{"key":"14_CR49","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","volume":"97","author":"JH Han","year":"2001","unstructured":"Han JH, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD (2001) Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 97:3349\u20133353","journal-title":"Blood"},{"key":"14_CR50","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","volume":"101","author":"S Lentzsch","year":"2003","unstructured":"Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY (2003) Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 101:3568\u20133573","journal-title":"Blood"},{"key":"14_CR51","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2007-05-093294","volume":"110","author":"S Vallet","year":"2007","unstructured":"Vallet S, Raje N, Ishitsuka K et al (2007) MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 110:3744\u20133752","journal-title":"Blood"},{"key":"14_CR52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/jsre.2001.6204","volume":"100","author":"AT Mancino","year":"2001","unstructured":"Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E (2001) Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 100:18\u201324","journal-title":"J Surg Res"},{"key":"14_CR53","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/gut.2004.044370","volume":"54","author":"AR Moschen","year":"2005","unstructured":"Moschen AR, Kaser A, Enrich B et al (2005) The RANKL\/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 54:479\u2013487","journal-title":"Gut"},{"key":"14_CR54","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S8756-3282(01)00682-2","volume":"30","author":"E Romas","year":"2002","unstructured":"Romas E, Gillespie MT, Martin TJ (2002) Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30:340\u2013346","journal-title":"Bone"},{"key":"14_CR55","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V98.7.2269","volume":"98","author":"C Seidel","year":"2001","unstructured":"Seidel C, Hjertner O, Abildgaard N et al (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98:2269\u20132271","journal-title":"Blood"},{"key":"14_CR56","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","volume":"98","author":"PI Croucher","year":"2001","unstructured":"Croucher PI, Shipman CM, Lippitt J et al (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98:3534\u20133540","journal-title":"Blood"},{"key":"14_CR57","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/sj.leu.2403423","volume":"18","author":"E Terpos","year":"2004","unstructured":"Terpos E, Politou M, Szydlo R et al (2004) Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL\/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 18:1420\u20131426","journal-title":"Leukemia"},{"key":"14_CR58","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/sj.leu.2403890","volume":"19","author":"E Terpos","year":"2005","unstructured":"Terpos E, Mihou D, Szydlo R et al (2005) The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory\/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL\/osteoprotegerin ratio. Leukemia 19:1969\u20131976","journal-title":"Leukemia"},{"key":"14_CR59","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.yexcr.2006.02.026","volume":"312","author":"AN Nguyen","year":"2006","unstructured":"Nguyen AN, Stebbins EG, Henson M et al (2006) Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res 312:1909\u20131923","journal-title":"Exp Cell Res"},{"key":"14_CR60","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2141.2008.07044.x","volume":"141","author":"K Ishitsuka","year":"2008","unstructured":"Ishitsuka K, Hideshima T, Neri P et al (2008) p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol 141:598\u2013606","journal-title":"Br J Haematol"},{"key":"14_CR61","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood-2008-08-173948","volume":"113","author":"Y Hiruma","year":"2009","unstructured":"Hiruma Y, Honjo T, Jelinek DF et al (2009) Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood 113:4894\u20134902","journal-title":"Blood"},{"key":"14_CR62","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.V85.7.1903.bloodjournal8571903","volume":"85","author":"M Urashima","year":"1995","unstructured":"Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC (1995) CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85:1903\u20131912","journal-title":"Blood"},{"key":"14_CR63","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1182\/blood-2011-05-353300","volume":"119","author":"G Xu","year":"2012","unstructured":"Xu G, Liu K, Anderson J et al (2012) Expression of XBP1\u00a0s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation. Blood 119:4205\u20134214","journal-title":"Blood"},{"key":"14_CR64","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","volume":"95","author":"B Dankbar","year":"2000","unstructured":"Dankbar B, Padro T, Leo R et al (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95:2630\u20132636","journal-title":"Blood"},{"key":"14_CR65","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","volume":"103","author":"J Moreaux","year":"2004","unstructured":"Moreaux J, Legouffe E, Jourdan E et al (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103:3148\u20133157","journal-title":"Blood"},{"key":"14_CR66","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","volume":"13","author":"P Neri","year":"2007","unstructured":"Neri P, Kumar S, Fulciniti MT et al (2007) Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res 13:5903\u20135909","journal-title":"Clin Cancer Res"},{"key":"14_CR67","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/leu.2011.60","volume":"25","author":"J Asano","year":"2011","unstructured":"Asano J, Nakano A, Oda A et al (2011) The serine\/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia 25:1182\u20131188","journal-title":"Leukemia"},{"key":"14_CR68","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mds068","volume":"23","author":"E Terpos","year":"2012","unstructured":"Terpos E, Kastritis E, Christoulas D et al (2012) Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol 23:2681\u20132686","journal-title":"Ann Oncol"},{"key":"14_CR69","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/leu.2014.147","volume":"29","author":"M Hiasa","year":"2015","unstructured":"Hiasa M, Teramachi J, Oda A et al (2015) Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. Leukemia 29:207\u2013217","journal-title":"Leukemia"},{"key":"14_CR70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","volume":"341","author":"JJ Westendorf","year":"2004","unstructured":"Westendorf JJ, Kahler RA, Schroeder TM (2004) Wnt signaling in osteoblasts and bone diseases. Gene 341:19\u201339","journal-title":"Gene"},{"key":"14_CR71","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R et al (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483\u20132494","journal-title":"N Engl J Med"},{"key":"14_CR72","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","volume":"106","author":"T Oshima","year":"2005","unstructured":"Oshima T, Abe M, Asano J et al (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106:3160\u20133165","journal-title":"Blood"},{"key":"14_CR73","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1158\/0008-5472.CAN-06-4666","volume":"67","author":"N Giuliani","year":"2007","unstructured":"Giuliani N, Morandi F, Tagliaferri S et al (2007) Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 67:7665\u20137674","journal-title":"Cancer Res"},{"key":"14_CR74","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","volume":"131","author":"E Terpos","year":"2012","unstructured":"Terpos E, Christoulas D, Katodritou E et al (2012) Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer 131:1466\u20131471","journal-title":"Int J Cancer"},{"key":"14_CR75","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/bcj.2011.22","volume":"1","author":"S Colucci","year":"2011","unstructured":"Colucci S, Brunetti G, Oranger A et al (2011) Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J 1:e27","journal-title":"Blood Cancer J"},{"key":"14_CR76","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/SPC.0000000000000090","volume":"8","author":"J Delgado-Calle","year":"2014","unstructured":"Delgado-Calle J, Bellido T, Roodman GD (2014) Role of osteocytes in multiple myeloma bone disease. Curr Opin Support Palliat Care 8:407\u2013413","journal-title":"Curr Opin Support Palliat Care"},{"key":"14_CR77","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMct1004903","volume":"363","author":"MJ Favus","year":"2010","unstructured":"Favus MJ (2010) Bisphosphonates for osteoporosis. N Engl J Med 363:2027\u20132035","journal-title":"N Engl J Med"},{"key":"14_CR78","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","volume":"104","author":"LI Plotkin","year":"1999","unstructured":"Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363\u20131374","journal-title":"J Clin Invest"},{"key":"14_CR79","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.lfs.2004.04.048","volume":"75","author":"G Kogianni","year":"2004","unstructured":"Kogianni G, Mann V, Ebetino F et al (2004) Fas\/CD95 is associated with glucocorticoid-induced osteocyte apoptosis. Life Sci 75:2879\u20132895","journal-title":"Life Sci"},{"key":"14_CR80","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bone.2006.02.060","volume":"39","author":"LI Plotkin","year":"2006","unstructured":"Plotkin LI, Manolagas SC, Bellido T (2006) Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts\/osteocytes with novel analogs. Bone 39:443\u2013452","journal-title":"Bone"},{"key":"14_CR81","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1074\/jbc.M412817200","volume":"280","author":"LI Plotkin","year":"2005","unstructured":"Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T (2005) Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem 280:7317\u20137325","journal-title":"J Biol Chem"},{"key":"14_CR82","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535\u20131541","journal-title":"Lancet"},{"key":"14_CR83","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"14_CR84","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98:1735\u20131744","journal-title":"Cancer"},{"key":"14_CR85","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 21:3150\u20133157","journal-title":"J Clin Oncol"},{"key":"14_CR86","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879\u2013882","journal-title":"J Natl Cancer Inst"},{"key":"14_CR87","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"JR Berenson","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L et al (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334:488\u2013493","journal-title":"N Engl J Med"},{"key":"14_CR88","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"P Major","year":"2001","unstructured":"Major P, Lortholary A, Hon J et al (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558\u2013567","journal-title":"J Clin Oncol"},{"key":"14_CR89","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","volume":"12","author":"M Gnant","year":"2011","unstructured":"Gnant M, Mlineritsch B, Stoeger H et al (2011) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 12:631\u2013641","journal-title":"Lancet Oncol"},{"key":"14_CR90","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","volume":"365","author":"RE Coleman","year":"2011","unstructured":"Coleman RE, Marshall H, Cameron D et al (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396\u20131405","journal-title":"N Engl J Med"},{"key":"14_CR91","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","volume":"376","author":"GJ Morgan","year":"2010","unstructured":"Morgan GJ, Davies FE, Gregory WM et al (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376:1989\u20131999","journal-title":"Lancet"},{"key":"14_CR92","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1158\/1078-0432.CCR-07-1430","volume":"14","author":"N Raje","year":"2008","unstructured":"Raje N, Woo SB, Hande K et al (2008) Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res 14:2387\u20132395","journal-title":"Clin Cancer Res"},{"key":"14_CR93","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","volume":"144","author":"SB Woo","year":"2006","unstructured":"Woo SB, Hellstein JW, Kalmar JR (2006) Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753\u2013761","journal-title":"Ann Intern Med"},{"key":"14_CR94","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.archoralbio.2012.09.016","volume":"58","author":"FG Basso","year":"2013","unstructured":"Basso FG, Turrioni AP, Hebling J, de Souza Costa CA (2013) Effects of zoledronic acid on odontoblast-like cells. Arch Oral Biol 58:467\u2013473","journal-title":"Arch Oral Biol"},{"key":"14_CR95","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.oraloncology.2009.01.002","volume":"45","author":"J Bagan","year":"2009","unstructured":"Bagan J, Scully C, Sabater V, Jimenez Y (2009) Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): a concise update. Oral Oncol 45:551\u2013554","journal-title":"Oral Oncol"},{"key":"14_CR96","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/14740338.7.4.491","volume":"7","author":"SJ Wimalawansa","year":"2008","unstructured":"Wimalawansa SJ (2008) Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf 7:491\u2013512","journal-title":"Expert Opin Drug Saf"},{"key":"14_CR97","first-page":"968","volume":"91","author":"MA Dimopoulos","year":"2006","unstructured":"Dimopoulos MA, Kastritis E, Anagnostopoulos A et al (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91:968\u2013971","journal-title":"Haematologica"},{"key":"14_CR98","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","volume":"134","author":"K Zervas","year":"2006","unstructured":"Zervas K, Verrou E, Teleioudis Z et al (2006) Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 134:620\u2013623","journal-title":"Br J Haematol"},{"key":"14_CR99","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(11)61374-3","volume":"378","author":"GJ Morgan","year":"2011","unstructured":"Morgan GJ (2011) Further analyses of the Myeloma IX Study. Lancet 378:768\u2013769","journal-title":"Lancet"},{"key":"14_CR100","first-page":"331","volume":"7","author":"AJ Yee","year":"2012","unstructured":"Yee AJ, Raje NS (2012) Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients. Clin Interv Aging 7:331\u2013338","journal-title":"Clin Interv Aging"},{"key":"14_CR101","doi-asserted-by":"crossref","unstructured":"Kobayashi E, Setsu N (2015) Osteosclerosis induced by denosumab. Lancet 385:539-6736(14)61338-6. Epub 2014 Oct 28","DOI":"10.1016\/S0140-6736(14)61338-6"},{"key":"14_CR102","doi-asserted-by":"crossref","unstructured":"Gossai N, Hilgers MV, Polgreen LE, Greengard EG (2015) Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer","DOI":"10.1002\/pbc.25393"},{"key":"14_CR103","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125\u20131132","journal-title":"J Clin Oncol"},{"key":"14_CR104","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","volume":"97","author":"JJ Body","year":"2003","unstructured":"Body JJ, Greipp P, Coleman RE et al (2003) A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97:887\u2013892","journal-title":"Cancer"},{"key":"14_CR105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","volume":"102","author":"BO Oyajobi","year":"2003","unstructured":"Oyajobi BO, Franchin G, Williams PJ et al (2003) Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 102:311\u2013319","journal-title":"Blood"},{"key":"14_CR106","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.exphem.2004.11.015","volume":"33","author":"Y Oba","year":"2005","unstructured":"Oba Y, Lee JW, Ehrlich LA et al (2005) MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 33:272\u2013278","journal-title":"Exp Hematol"},{"key":"14_CR107","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2011-10-384784","volume":"120","author":"DJ Dairaghi","year":"2012","unstructured":"Dairaghi DJ, Oyajobi BO, Gupta A et al (2012) CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood 120:1449\u20131457","journal-title":"Blood"},{"key":"14_CR108","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, Darce JR, Arendt BK et al (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103:689\u2013694","journal-title":"Blood"},{"key":"14_CR109","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nri844","volume":"2","author":"F Mackay","year":"2002","unstructured":"Mackay F, Browning JL (2002) BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2:465\u2013475","journal-title":"Nat Rev Immunol"},{"key":"14_CR110","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","volume":"285","author":"PA Moore","year":"1999","unstructured":"Moore PA, Belvedere O, Orr A et al (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260\u2013263","journal-title":"Science"},{"key":"14_CR111","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","volume":"106","author":"J Moreaux","year":"2005","unstructured":"Moreaux J, Cremer FW, Reme T et al (2005) The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106:1021\u20131030","journal-title":"Blood"},{"key":"14_CR112","doi-asserted-by":"crossref","first-page":"7082","DOI":"10.1073\/pnas.0711263105","volume":"105","author":"RS Pearsall","year":"2008","unstructured":"Pearsall RS, Canalis E, Cornwall-Brady M et al (2008) A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA 105:7082\u20137087","journal-title":"Proc Natl Acad Sci USA"},{"key":"14_CR113","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","volume":"24","author":"J Ruckle","year":"2009","unstructured":"Ruckle J, Jacobs M, Kramer W et al (2009) Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 24:744\u2013752","journal-title":"J Bone Miner Res"},{"key":"14_CR114","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.bone.2013.01.012","volume":"53","author":"S Pozzi","year":"2013","unstructured":"Pozzi S, Fulciniti M, Yan H et al (2013) In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone 53:487\u2013496","journal-title":"Bone"},{"key":"14_CR115","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2008-11-191577","volume":"114","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, Tassone P, Hideshima T et al (2009) Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114:371\u2013379","journal-title":"Blood"},{"key":"14_CR116","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","volume":"109","author":"S Yaccoby","year":"2007","unstructured":"Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109:2106\u20132111","journal-title":"Blood"},{"key":"14_CR117","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","volume":"24","author":"DJ Heath","year":"2009","unstructured":"Heath DJ, Chantry AD, Buckle CH et al (2009) Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 24:425\u2013436","journal-title":"J Bone Miner Res"},{"key":"14_CR118","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14728220902841961","volume":"13","author":"LH Hoeppner","year":"2009","unstructured":"Hoeppner LH, Secreto FJ, Westendorf JJ (2009) Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets 13:485\u2013496","journal-title":"Expert Opin Ther Targets"},{"key":"14_CR119","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrrheum.2011.130","volume":"7","author":"EM Lewiecki","year":"2011","unstructured":"Lewiecki EM (2011) New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol 7:631\u2013638","journal-title":"Nat Rev Rheumatol"},{"key":"14_CR120","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"14_CR121","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","volume":"29","author":"J McColm","year":"2014","unstructured":"McColm J, Hu L, Womack T, Tang CC, Chiang AY (2014) Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 29:935\u2013943","journal-title":"J Bone Miner Res"},{"key":"14_CR122","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.maturitas.2014.04.016","volume":"78","author":"BL Clarke","year":"2014","unstructured":"Clarke BL (2014) Anti-sclerostin antibodies: utility in treatment of osteoporosis. Maturitas 78:199\u2013204","journal-title":"Maturitas"},{"key":"14_CR123","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","volume":"21","author":"I Metzler von","year":"2007","unstructured":"von Metzler I, Krebbel H, Hecht M et al (2007) Bortezomib inhibits human osteoclastogenesis. Leukemia 21:2025\u20132034","journal-title":"Leukemia"},{"key":"14_CR124","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","volume":"131","author":"M Zangari","year":"2005","unstructured":"Zangari M, Esseltine D, Lee CK et al (2005) Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 131:71\u201373","journal-title":"Br J Haematol"},{"key":"14_CR125","first-page":"491","volume":"118","author":"S Mukherjee","year":"2008","unstructured":"Mukherjee S, Raje N, Schoonmaker JA et al (2008) Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 118:491\u2013504","journal-title":"J Clin Invest"},{"key":"14_CR126","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","volume":"110","author":"N Giuliani","year":"2007","unstructured":"Giuliani N, Morandi F, Tagliaferri S et al (2007) The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 110:334\u2013338","journal-title":"Blood"},{"key":"14_CR127","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","volume":"135","author":"E Terpos","year":"2006","unstructured":"Terpos E, Heath DJ, Rahemtulla A et al (2006) Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 135:688\u2013692","journal-title":"Br J Haematol"},{"key":"14_CR128","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","volume":"110","author":"DJ Kuhn","year":"2007","unstructured":"Kuhn DJ, Chen Q, Voorhees PM et al (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110:3281\u20133290","journal-title":"Blood"},{"key":"14_CR129","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/leu.2012.183","volume":"27","author":"MA Hurchla","year":"2013","unstructured":"Hurchla MA, Garcia-Gomez A, Hornick MC et al (2013) The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia 27:430\u2013440","journal-title":"Leukemia"},{"key":"14_CR130","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1021\/nn5009879","volume":"8","author":"SW Ha","year":"2014","unstructured":"Ha SW, Weitzmann MN, Beck GR Jr (2014) Bioactive silica nanoparticles promote osteoblast differentiation through stimulation of autophagy and direct association with LC3 and p62. ACS Nano 8:5898\u20135910","journal-title":"ACS Nano"},{"key":"14_CR131","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/leu.2014.69","volume":"28","author":"H Eda","year":"2014","unstructured":"Eda H, Santo L, Cirstea DD et al (2014) A novel Bruton\u2019s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. Leukemia 28:1892\u20131901","journal-title":"Leukemia"},{"key":"14_CR132","doi-asserted-by":"crossref","unstructured":"Brown JR (2013) Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leuk Lymphoma","DOI":"10.3109\/10428194.2013.803226"},{"key":"14_CR133","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1182\/blood-2011-12-396853","volume":"120","author":"YT Tai","year":"2012","unstructured":"Tai YT, Chang BY, Kong SY et al (2012) Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120:1877\u20131887","journal-title":"Blood"},{"key":"14_CR134","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ajh.23433","volume":"88","author":"R Bam","year":"2013","unstructured":"Bam R, Ling W, Khan S et al (2013) Role of Bruton\u2019s tyrosine kinase in myeloma cell migration and induction of bone disease. Am J Hematol 88:463\u2013471","journal-title":"Am J Hematol"}],"container-title":["Cancer Treatment and Research","Plasma Cell Dyscrasias"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-40320-5_14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T18:27:40Z","timestamp":1718821660000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-40320-5_14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9783319403182","9783319403205"],"references-count":134,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-40320-5_14","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}